Pacira | PCRX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Astellas Pharma JPY 482.54B 38.28B 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Cara Therapeutics USD 2.57M 1.11M 2025-03
Coherus Biosciences USD 8.7M 853K 2025-12
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
J&J USD 18.55B 1.31B 2026-06
Ligand Pharmaceuticals USD 100.41M 51.96M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Novo Nordisk DKK 64.01B 1.19B 2025-06
Omeros USD -33.16M 18.52M 2024-06
Pacira USD 133.91M 7.27M 2026-06
Perrigo USD 313.9M 11.6M 2026-06
Pfizer USD -248M 11.29B 2026-06
Supernus Pharmaceuticals USD 160.06M 30.7M 2026-06
Teva Pharmaceutical Industries USD 2.15B 45M 2026-06
Xeris Pharmaceuticals USD 72.55M 404K 2026-03
Zoetis USD 1.76B 140M 2026-06